tiprankstipranks
Oric Pharmaceuticals reports Q4 EPS (52c), consensus (55c)
The Fly

Oric Pharmaceuticals reports Q4 EPS (52c), consensus (55c)

Cash, cash equivalents and investments totaled $228.2M as of December 31 , which the company expects will be sufficient to fund its operating plan into the first half of 2025.."We had a productive 2022, during which we made significant progress across our clinical pipeline, advanced multiple preclinical discovery programs, and further strengthened the balance sheet," said Jacob M. Chacko, MD, chief executive officer. "We commenced dosing for all three Phase 1b trials in 2022 and selected a drug candidate for our potential first-in-class PLK4 inhibitor. We are pleased with the ongoing enrollment across our three Phase 1b trials and are looking forward to sharing initial clinical data for ORIC-533, ORIC-114, and ORIC-944 in the second half of 2023."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ORIC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles